Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 6:12 pm Unchanged | 2025-11-12 | 13D | Lineage Cell Therapeutics, Inc. LCTX | Broadwood Partners, L.P. | 57,848,357 23.100% | 0 (Unchanged) | Filing History |
| 2025-09-26 11:52 am Purchase | 2025-09-22 | 13G | Lineage Cell Therapeutics, Inc. LCTX | Chernett Jorey | 11,445,003 5.000% | 11,445,003 (New Position) | Filing History |
| 2025-07-17 7:54 pm Sale | 2025-06-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 2,234,545 1.000% | -9,218,760 (-80.49%) | Filing History |
| 2025-04-24 08:48 am Purchase | 2025-03-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 11,453,305 5.000% | 1,358,628 (+13.46%) | Filing History |
| 2025-02-05 5:28 pm Purchase | 2024-12-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 10,094,677 4.600% | 174,877 (+1.76%) | Filing History |
| 2025-01-28 8:07 pm Purchase | 2025-01-27 | 13D | Lineage Cell Therapeutics, Inc. LCTX | Broadwood Partners, L.P. | 57,848,357 24.500% | 15,789,474 (+37.54%) | Filing History |
| 2024-11-21 8:05 pm Purchase | 2024-11-19 | 13D | Lineage Cell Therapeutics, Inc. LCTX | Broadwood Partners, L.P. | 42,058,883 19.100% | 75,000 (+0.18%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 9,919,800 5.300% | 0 (Unchanged) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 9,919,800 5.300% | 6,164,043 (+164.12%) | Filing History |
| 2024-02-08 6:57 pm Purchase | 2024-02-06 | 13D | Lineage Cell Therapeutics, Inc. LCTX | Broadwood Partners, L.P. | 41,983,883 22.200% | 6,756,610 (+19.18%) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 3,755,757 2.200% | -6,252,753 (-62.47%) | Filing History |
| 2022-03-25 5:23 pm Purchase | 2022-03-10 | 13D | Lineage Cell Therapeutics, Inc. LCTX | Broadwood Partners, L.P. | 35,227,273 20.700% | 980,106 (+2.86%) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 10,008,510 5.900% | 10,008,510 (New Position) | Filing History |
| 2021-03-16 5:04 pm Purchase | 2021-03-11 | 13D | Lineage Cell Therapeutics, Inc. LCTX | Broadwood Partners, L.P. | 34,247,167 21.200% | 34,247,167 (New Position) | Filing History |